FR2602423B1
(fr)
*
|
1986-08-08 |
1989-05-05 |
Ethypharm Sa |
Procede de preparation d'un medicament a base de fenofibrate, medicament obtenu par ce procede
|
FR2627696B1
(fr)
*
|
1988-02-26 |
1991-09-13 |
Fournier Innovation Synergie |
Nouvelle forme galenique du fenofibrate
|
DE69127275T2
(de)
*
|
1991-06-21 |
1998-03-12 |
Ilsan Ilac Ve Hammaddeleri San |
Neues galenisches Verfahren für Omeprazol enthaltende Pellets
|
US5167964A
(en)
*
|
1992-02-14 |
1992-12-01 |
Warner-Lambert Company |
Semi-enteric drug delivery systems and methods for preparing same
|
US5571531A
(en)
*
|
1994-05-18 |
1996-11-05 |
Mcmaster University |
Microparticle delivery system with a functionalized silicone bonded to the matrix
|
FR2730231B1
(fr)
*
|
1995-02-02 |
1997-04-04 |
Fournier Sca Lab |
Association de fenofibrate et de vitamine e, utilisation en therapeutique
|
US7008668B2
(en)
*
|
1995-05-09 |
2006-03-07 |
Phoqus Pharmaceuticals Limited |
Powder coating composition for electrostatic coating of pharmaceutical substrates
|
CA2220506C
(en)
*
|
1995-05-09 |
2008-01-08 |
Colorcon Limited |
Powder coating composition for electrostatic coating of pharmaceutical substrates
|
FR2737121B1
(fr)
*
|
1995-07-27 |
1997-10-03 |
Cl Pharma |
Nouvelles formulations galeniques du fenofibrate et leurs applications
|
DE19608750A1
(de)
*
|
1996-03-06 |
1997-09-11 |
Durachemie Gmbh & Co Kg |
Verfahren zur Herstellung von Fenofibrat-Präparaten
|
US7255877B2
(en)
*
|
1996-08-22 |
2007-08-14 |
Jagotec Ag |
Fenofibrate microparticles
|
US6465016B2
(en)
|
1996-08-22 |
2002-10-15 |
Research Triangle Pharmaceuticals |
Cyclosporiine particles
|
ZA978537B
(en)
|
1996-09-23 |
1998-05-12 |
Focal Inc |
Polymerizable biodegradable polymers including carbonate or dioxanone linkages.
|
GB9623634D0
(en)
*
|
1996-11-13 |
1997-01-08 |
Bpsi Holdings Inc |
Method and apparatus for the coating of substrates for pharmaceutical use
|
FR2758459B1
(fr)
*
|
1997-01-17 |
1999-05-07 |
Pharma Pass |
Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
|
US6979456B1
(en)
|
1998-04-01 |
2005-12-27 |
Jagotec Ag |
Anticancer compositions
|
KR100635456B1
(ko)
|
1998-05-29 |
2006-10-18 |
스키에파마 캐나다 인코포레이티드 |
열보호화 마이크로입자 조성물 및 그의 말단의 스팀멸균방법
|
IL141095A0
(en)
|
1998-08-19 |
2002-02-10 |
Rtp Pharma Inc |
Injectable aqueous dispersions of propofol
|
US7939105B2
(en)
*
|
1998-11-20 |
2011-05-10 |
Jagotec Ag |
Process for preparing a rapidly dispersing solid drug dosage form
|
SA99191255B1
(ar)
|
1998-11-30 |
2006-11-25 |
جي دي سيرل اند كو |
مركبات سيليكوكسيب celecoxib
|
US6838091B2
(en)
|
1998-12-18 |
2005-01-04 |
Abbott Laboratories |
Formulations comprising lipid-regulating agents
|
US7014864B1
(en)
|
1998-12-18 |
2006-03-21 |
Abbott Laboratories |
Formulations comprising lipid-regulating agents
|
US6814977B1
(en)
|
1998-12-18 |
2004-11-09 |
Abbott Laboratories |
Formulations comprising lipid-regulating agents
|
US6180138B1
(en)
|
1999-01-29 |
2001-01-30 |
Abbott Laboratories |
Process for preparing solid formulations of lipid-regulating agents with enhanced dissolution and absorption
|
US6383517B1
(en)
|
1999-01-29 |
2002-05-07 |
Abbott Laboratories |
Process for preparing solid formulations of lipid-regulating agents with enhanced dissolution and absorption
|
US6368622B2
(en)
|
1999-01-29 |
2002-04-09 |
Abbott Laboratories |
Process for preparing solid formulations of lipid regulating agents with enhanced dissolution and absorption
|
US6270807B1
(en)
|
1999-03-02 |
2001-08-07 |
L. Perrigo Company |
Taste-masked pharmaceutical composition
|
US6719999B2
(en)
|
1999-03-31 |
2004-04-13 |
Abbott Laboratories |
Formulations comprising lipid-regulating agents
|
US6465011B2
(en)
|
1999-05-29 |
2002-10-15 |
Abbott Laboratories |
Formulations comprising lipid-regulating agents
|
US6372251B2
(en)
|
1999-06-11 |
2002-04-16 |
Abbott Laboratories |
Formulations comprising lipid-regulating agents
|
US6982281B1
(en)
*
|
2000-11-17 |
2006-01-03 |
Lipocine Inc |
Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
|
US7863331B2
(en)
|
1999-07-09 |
2011-01-04 |
Ethypharm |
Pharmaceutical composition containing fenofibrate and method for the preparation thereof
|
FR2795961B1
(fr)
*
|
1999-07-09 |
2004-05-28 |
Ethypharm Lab Prod Ethiques |
Composition pharmaceutique contenant du fenofibrate micronise, un tensioactif et un derive cellulosique liant et procede de preparation
|
WO2001021154A2
(en)
*
|
1999-09-21 |
2001-03-29 |
Rtp Pharma Inc. |
Surface modified particulate compositions of biologically active substances
|
GB0002305D0
(en)
*
|
2000-02-01 |
2000-03-22 |
Phoqus Limited |
Power material for electrostatic application
|
JP5102423B2
(ja)
|
2000-04-20 |
2012-12-19 |
オバン・エナジー・リミテッド |
改善された水不溶性薬剤粒子の処理
|
US6531158B1
(en)
|
2000-08-09 |
2003-03-11 |
Impax Laboratories, Inc. |
Drug delivery system for enhanced bioavailability of hydrophobic active ingredients
|
JP2004509146A
(ja)
*
|
2000-09-20 |
2004-03-25 |
スカイファーマ・カナダ・インコーポレーテッド |
安定化フィブレート微粒子
|
US8586094B2
(en)
*
|
2000-09-20 |
2013-11-19 |
Jagotec Ag |
Coated tablets
|
US6982251B2
(en)
*
|
2000-12-20 |
2006-01-03 |
Schering Corporation |
Substituted 2-azetidinones useful as hypocholesterolemic agents
|
AR034204A1
(es)
*
|
2001-01-26 |
2004-02-04 |
Schering Corp |
Composiciones y combinaciones de acido nicotinico y derivados del mismo con inhibidor(es) de la absorcion de los esteroles, y el uso de los mismos para preparar medicamentos para el tratamiento para indicaciones vasculares
|
AR033855A1
(es)
*
|
2001-01-26 |
2004-01-07 |
Schering Corp |
Composiciones y combinaciones de activador(es) del receptor de activacion de proliferacion peroxis0mal (ppar) e inhibidor(es) de absorcion de esterol, el uso de dichas composiciones o combinaciones para la manufactura de un medicamento para el tratamiento para indicaciones vasculares, diabetes, obes
|
US7071181B2
(en)
*
|
2001-01-26 |
2006-07-04 |
Schering Corporation |
Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
|
DK1385548T3
(da)
*
|
2001-01-26 |
2007-09-10 |
Schering Corp |
Kombinationer af sterolabsorptionsinhibitor(er) med (et eller flere) kardiovaskulære midler til behandling af vaskulære tilstande
|
WO2002058734A2
(en)
*
|
2001-01-26 |
2002-08-01 |
Schering Corporation |
Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions
|
WO2002058733A2
(en)
*
|
2001-01-26 |
2002-08-01 |
Schering Corporation |
Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications
|
TWI337076B
(en)
*
|
2001-01-26 |
2011-02-11 |
Schering Corp |
The use of substituted azetidinone compounds for the treatment of sitosterolemia
|
US20060287254A1
(en)
*
|
2001-01-26 |
2006-12-21 |
Schering Corporation |
Use of substituted azetidinone compounds for the treatment of sitosterolemia
|
DE60127457T2
(de)
*
|
2001-02-22 |
2007-11-29 |
Jagotec Ag |
Fibrat-statin kombinationen mit verminderten von der nahrungsaufnahme abhängigen auswirkungen
|
AR038956A1
(es)
*
|
2001-05-25 |
2005-02-02 |
Schering Corp |
Uso de un compuesto que regula la produccion o niveles de peptidos beta amiloides para la manufactura de un medicamento para tratar la enfermedad de alzheimer y/o para regular dichos niveles de peptidos amiloides beta en un sujeto
|
PT1429756E
(pt)
*
|
2001-09-21 |
2007-01-31 |
Schering Corp |
Tratamento de xantoma com derivados de azetidinona como inibidores de absorção de esteróis
|
US7056906B2
(en)
*
|
2001-09-21 |
2006-06-06 |
Schering Corporation |
Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
|
DE60229406D1
(de)
*
|
2001-09-21 |
2008-11-27 |
Schering Corp |
Verfahren zur behandlung oder verhinderung von vaskulärer entzündung mit sterol-absorbierungs- inhibitor(en)
|
US20030119808A1
(en)
*
|
2001-09-21 |
2003-06-26 |
Schering Corporation |
Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects
|
US7053080B2
(en)
*
|
2001-09-21 |
2006-05-30 |
Schering Corporation |
Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
|
CN1288764C
(zh)
*
|
2002-09-17 |
2006-12-06 |
日本电信电话株式会社 |
半导体光调制器和具有光调制器的激光器
|
AU2003291719A1
(en)
*
|
2002-11-06 |
2004-06-03 |
Schering Corporation |
Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
|
CN100367947C
(zh)
*
|
2002-12-04 |
2008-02-13 |
徐州恩华赛德药业有限责任公司 |
具有抗高血脂症的含非诺贝特的药物组合物
|
US7259186B2
(en)
*
|
2002-12-17 |
2007-08-21 |
Abbott Laboratories |
Salts of fenofibric acid and pharmaceutical formulations thereof
|
US20080051411A1
(en)
*
|
2002-12-17 |
2008-02-28 |
Cink Russell D |
Salts of Fenofibric Acid and Pharmaceutical Formulations Thereof
|
ATE359777T1
(de)
*
|
2002-12-17 |
2007-05-15 |
Abbott Gmbh & Co Kg |
Fenofibratsäure enthaltende pharmazeutische zusammensetzung und deren physiologisch verträgliche salze und derivate
|
EP1832285A1
(en)
*
|
2002-12-17 |
2007-09-12 |
Abbott GmbH & Co. KG |
Formulation comprising fenofibric acid or a physiologically acceptable salt thereof
|
CN1756755A
(zh)
|
2003-03-07 |
2006-04-05 |
先灵公司 |
取代的2-吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
|
US7459442B2
(en)
*
|
2003-03-07 |
2008-12-02 |
Schering Corporation |
Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
|
MXPA05009503A
(es)
|
2003-03-07 |
2005-10-18 |
Schering Corp |
Compuestos de azetidinona sustituidos, formulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
|
CA2517572C
(en)
*
|
2003-03-07 |
2011-12-13 |
Schering Corporation |
Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
|
GB2402895B
(en)
*
|
2003-06-18 |
2006-08-23 |
Phoqus Pharmaceuticals Ltd |
Method and apparatus for the application of powder material to substrates
|
BRPI0415121A
(pt)
*
|
2003-10-10 |
2006-11-28 |
Lifecycle Pharma As |
material particulado, forma de dosagem sólida, método para fabricar a mesma, e, uso de um material particulado ou de uma forma de dosagem sólida
|
US20050096390A1
(en)
*
|
2003-10-10 |
2005-05-05 |
Per Holm |
Compositions comprising fenofibrate and pravastatin
|
US20050096391A1
(en)
*
|
2003-10-10 |
2005-05-05 |
Per Holm |
Compositions comprising fenofibrate and rosuvastatin
|
EP1680091B1
(en)
*
|
2003-10-10 |
2017-05-31 |
Veloxis Pharmaceuticals A/S |
A solid dosage form comprising a fibrate
|
US9173847B2
(en)
*
|
2003-10-10 |
2015-11-03 |
Veloxis Pharmaceuticals A/S |
Tablet comprising a fibrate
|
US20070014846A1
(en)
*
|
2003-10-10 |
2007-01-18 |
Lifecycle Pharma A/S |
Pharmaceutical compositions comprising fenofibrate and atorvastatin
|
EP1680189A2
(en)
*
|
2003-11-05 |
2006-07-19 |
Schering Corporation |
Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
|
US8062664B2
(en)
*
|
2003-11-12 |
2011-11-22 |
Abbott Laboratories |
Process for preparing formulations of lipid-regulating drugs
|
GB0330171D0
(en)
*
|
2003-12-30 |
2004-02-04 |
Phoqus Pharmaceuticals Ltd |
Method and apparatus for the application of powder material to substrates
|
GB0407312D0
(en)
*
|
2004-03-31 |
2004-05-05 |
Phoqus Pharmaceuticals Ltd |
Method and apparatus for the application of powder material to substrates
|
US20060177512A1
(en)
*
|
2004-04-05 |
2006-08-10 |
Yihong Qiu |
Process for preparing formulations of lipid-regulating drugs
|
WO2006033435A1
(ja)
*
|
2004-09-24 |
2006-03-30 |
Hi-Lex Corporation |
生体硬組織または軟組織誘導性スカフォールド材料
|
US20080152714A1
(en)
*
|
2005-04-08 |
2008-06-26 |
Yi Gao |
Pharmaceutical Formulations
|
EP1921919B1
(en)
*
|
2005-07-14 |
2012-04-04 |
Lithera, Inc. |
Sustained release enhanced lipolytic formulation for regional adipose tissue treatment
|
EP1785133A1
(en)
|
2005-11-10 |
2007-05-16 |
Laboratoires Fournier S.A. |
Use of fenofibrate or a derivative thereof for preventing diabetic retinopathy
|
US20090074872A1
(en)
*
|
2006-06-26 |
2009-03-19 |
Mutual Pharmaceutical Company, Inc. |
Active Agent Formulations, Methods of Making, and Methods of Use
|
US20080050450A1
(en)
*
|
2006-06-26 |
2008-02-28 |
Mutual Pharmaceutical Company, Inc. |
Active Agent Formulations, Methods of Making, and Methods of Use
|
US20100119609A1
(en)
*
|
2006-10-17 |
2010-05-13 |
John Daniel Dobak |
Methods, compositions, and formulations for the treatment of thyroid eye disease
|
RU2417100C2
(ru)
*
|
2006-10-17 |
2011-04-27 |
Литера, Инк. |
Способы, композиции и препараты для лечения тиреоидной офтальмопатии
|
SI2200588T1
(sl)
*
|
2007-09-25 |
2019-08-30 |
Solubest Ltd. |
Sestavki, ki obsegajo lipofilne aktivne spojine, in postopek za njihovo pripravo
|
US20090202649A1
(en)
*
|
2008-02-06 |
2009-08-13 |
Subhash Gore |
Fenofibrate formulations
|
DE102008037025C5
(de)
*
|
2008-08-08 |
2016-07-07 |
Jesalis Pharma Gmbh |
Verfahren zur Herstellung kristalliner Wirkstoff-Mikropartikel bzw. einer Wirkstoffpartikel-Festkörperform
|
FR2940118B1
(fr)
|
2008-12-24 |
2013-08-09 |
Ethypharm Sa |
Formulation pharmaceutique de fenofibrate nanonise
|
US20100159010A1
(en)
*
|
2008-12-24 |
2010-06-24 |
Mutual Pharmaceutical Company, Inc. |
Active Agent Formulations, Methods of Making, and Methods of Use
|
US11304960B2
(en)
|
2009-01-08 |
2022-04-19 |
Chandrashekar Giliyar |
Steroidal compositions
|
US9132084B2
(en)
|
2009-05-27 |
2015-09-15 |
Neothetics, Inc. |
Methods for administration and formulations for the treatment of regional adipose tissue
|
US20110217369A1
(en)
*
|
2009-09-03 |
2011-09-08 |
Ranbaxy Laboratories Limited |
Fenofibrate compositions
|
JP2013517294A
(ja)
*
|
2010-01-15 |
2013-05-16 |
リセラ,インク. |
凍結乾燥ケーキ製剤
|
KR101202994B1
(ko)
|
2010-04-12 |
2012-11-21 |
한미사이언스 주식회사 |
페노피브린산 및 알칼리화제를 포함하는 경구용 약학 조성물
|
MX2013005873A
(es)
|
2010-11-24 |
2013-08-07 |
Lithera Inc |
Formulaciones monoterapeuticas de agonistas beta selectivo, lipofilo y de accion prolongada y procedimientos para el tratamiento cosmetico de adiposidad y abultamiento del contorno.
|
US9358241B2
(en)
|
2010-11-30 |
2016-06-07 |
Lipocine Inc. |
High-strength testosterone undecanoate compositions
|
US9034858B2
(en)
|
2010-11-30 |
2015-05-19 |
Lipocine Inc. |
High-strength testosterone undecanoate compositions
|
US20180153904A1
(en)
|
2010-11-30 |
2018-06-07 |
Lipocine Inc. |
High-strength testosterone undecanoate compositions
|
US20120148675A1
(en)
|
2010-12-10 |
2012-06-14 |
Basawaraj Chickmath |
Testosterone undecanoate compositions
|
US8722083B2
(en)
|
2012-06-25 |
2014-05-13 |
Mylan, Inc. |
Fenofibrate formulation
|
EP2842547A1
(en)
|
2013-08-27 |
2015-03-04 |
Freund Pharmatec Ltd. |
Improved fenofibrate compositions
|
CN105636582A
(zh)
|
2013-09-18 |
2016-06-01 |
乔治城大学 |
用非诺贝特及其类似物治疗神经退行性疾病
|
EP2878311A1
(en)
|
2013-11-27 |
2015-06-03 |
Freund Pharmatec Ltd. |
Solubility Enhancement for Hydrophobic Drugs
|
WO2016033556A1
(en)
|
2014-08-28 |
2016-03-03 |
Lipocine Inc. |
BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS
|
WO2016033549A2
(en)
|
2014-08-28 |
2016-03-03 |
Lipocine Inc. |
(17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
|
WO2016205423A2
(en)
|
2015-06-15 |
2016-12-22 |
Lipocine Inc. |
Composition and method for oral delivery of androgen prodrugs
|
US11559530B2
(en)
|
2016-11-28 |
2023-01-24 |
Lipocine Inc. |
Oral testosterone undecanoate therapy
|
AU2019308326A1
(en)
|
2018-07-20 |
2021-03-18 |
Lipocine Inc. |
Liver disease
|